|
Oct 10
|
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
|
Oct 7
|
Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
|
|
Sep 4
|
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
|
|
Sep 3
|
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
|
|
May 15
|
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
|
|
May 14
|
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
|
|
May 13
|
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
|
|
May 8
|
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
|
|
May 7
|
Sidoti Events, LLC's Virtual May Micro-Cap Conference
|
|
May 1
|
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
|
|
Apr 9
|
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
|
|
Apr 4
|
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
|
|
Apr 3
|
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
|
|
Apr 2
|
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
|
|
Mar 22
|
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Mar 19
|
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Mar 12
|
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
|
|
Mar 6
|
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
|
|
Nov 3
|
Genprex to Present at BIO-Europe 2023
|
|
Aug 31
|
Genprex Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation
|